InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GALECTIN THERAPEUTICS INC

GALT Clue Score21
United States Fiscal year ends December CIK 0001133416
$3.94 +8.24% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.94 +10.67% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2016Operating income−21.5Net income−21.4Fiscal year 2017Operating income−16.2Net income−16.2Fiscal year 2018Operating income−13.6Net income−13.9Fiscal year 2019Operating income−13.4Net income−13.3Fiscal year 2020Operating income−23.4Net income−23.5EPS, diluted−0.41Fiscal year 2021Operating income−30.2Net income−30.5EPS, diluted−0.52Fiscal year 2022Operating income−38.4Net income−38.8EPS, diluted−0.65Fiscal year 2023Operating income−38.1Net income−41.1EPS, diluted−0.74Fiscal year 2024Operating income−42.4Net income−47.0EPS, diluted−0.76Fiscal year 2025Operating income−20.1Net income−30.8EPS, diluted−0.48
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −21.5 −16.2 −13.6 −13.4 −23.4 −30.2 −38.4 −38.1 −42.4 −20.1
Net income −21.4 −16.2 −13.9 −13.3 −23.5 −30.5 −38.8 −41.1 −47.0 −30.8
Growth
EPS, diluted n/a n/a n/a n/a −0.41 −0.52 −0.65 −0.74 −0.76 −0.48
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2016Operating cash flow−16.4Fiscal year 2017Operating cash flow−15.9Fiscal year 2018Operating cash flow−10.2Fiscal year 2019Operating cash flow−10.8Fiscal year 2020Operating cash flow−20.6Fiscal year 2021Operating cash flow−24.3Fiscal year 2022Operating cash flow−31.1Fiscal year 2023Operating cash flow−33.0Fiscal year 2024Operating cash flow−41.8Fiscal year 2025Operating cash flow−23.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −16.4 −15.9 −10.2 −10.8 −20.6 −24.3 −31.1 −33.0 −41.8 −23.9

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash15.4Shareholders’ equity10.3Fiscal year 2017Cash3.1Shareholders’ equity−0.5Fiscal year 2018Cash8.3Shareholders’ equity5.2Fiscal year 2019Cash47.5Shareholders’ equity43.9Fiscal year 2020Cash27.1Shareholders’ equity22.5Fiscal year 2021Cash39.6Shareholders’ equity0.9Fiscal year 2022Cash18.6Shareholders’ equity−33.9Fiscal year 2023Cash25.7Shareholders’ equity−62.0Fiscal year 2024Cash15.1Shareholders’ equity−104.8Fiscal year 2025Cash17.7Shareholders’ equity−127.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 15.4 3.1 8.3 47.5 27.1 39.6 18.6 25.7 15.1 17.7
Shareholders’ equity 10.3 −0.5 5.2 43.9 22.5 0.9 −33.9 −62.0 −104.8 −127.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−16.4 −15.9 −10.2 −10.8 −20.6 −24.3 −31.1 −33.0 −41.8 −23.9
Growth
0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a n/a
Investment
n/a 0.0 0.0 n/a 0.0 0.0 0.0 0.0 0.0 0.0
Financing
n/a 3.6 15.4 50.1 0.3 36.8 10.0 40.0 31.2 26.5

Capital expenditure, dividends and buybacks are shown as money out, so negative.